

JPET#233924

Title Page

Task- and treatment length-dependent effects of vortioxetine on scopolamine-induced cognitive dysfunction and hippocampal extracellular acetylcholine in rats

Alan L. Pehrson, Todd M. Hillhouse, Nasser Haddjeri, Renaud Rovera, Joseph H. Porter, Arne Mørk, Gennady Smagin, Dekun Song, David Budac, Manuel Cajina, Connie Sanchez

Lundbeck Research USA, Inc., Paramus, New Jersey, United States of America (ALP, GNS, DS, DB, MC, CS)

Translational Neuropsychiatry Unit, Department of Clinical Medicine, Aarhus University, Risskov, Denmark (CS) Department of Pharmacology, University of Michigan, Ann Arbor, Michigan (TMH)

Psychology Department, Virginia Commonwealth University, Richmond, Virginia (TMH, JHP)

INSERM U846, Stem Cell and Brain Research Institute, F-69500 Bron, France (RR, NH)

H. Lundbeck A/S, Valby, Denmark (ARM)

JPET#233924

Running Title Page

RUNNING TITLE: Vortioxetine on scopolamine-induced cognitive impairment

*Corresponding author: Connie Sanchez, D.Sc.

Number of pages: 46

Number of tables: 2

Number of figures: 6

Number of references: 48

Number of words in Abstract: 249

Number of words in Introduction: 674

Number of words in Discussion: 1500

Nonstandard abbreviations:

5-HT, serotonin, ACh - acetylcholine, aCSF – artificial cerebrospinal fluid, GABA - gamma-aminobutyric acid, IT – information trial, MDD – Major Depressive Disorder, RT – retention trial, s.c. – subcutaneous, SERT – serotonin transporter, VSdT – visual signal detection task

Recommended Section Assignment: Behavioral Pharmacology

JPET#233924

Abstract

Major Depressive Disorder (MDD) is a common psychiatric disorder that often features impairments in cognitive function, and these cognitive symptoms can be important determinants of functional ability. Vortioxetine is a multimodal antidepressant that may improve some aspects of cognitive function in patients with MDD, including attention, processing speed, executive function and memory. However, the cause of these effects is unclear, and there are several competing theories on the underlying mechanism, notably including regionally-selective downstream enhancement of glutamate neurotransmission, and increased acetylcholine (ACh) neurotransmission. The current work sought to evaluate the ACh hypothesis by examining vortioxetine's ability to reverse scopolamine-induced impairments in rodent tests of memory and attention. Additionally, vortioxetine's effects on hippocampal extracellular ACh levels were examined alongside studies of vortioxetine's pharmacokinetic profile. We found that acute vortioxetine reversed scopolamine-induced impairments in social and object recognition memory, but did not alter scopolamine-induced impairments in attention. Acute vortioxetine also induced a modest and short-lived increase in hippocampal ACh levels. However, this short-term effect is at variance with vortioxetine's moderately long brain half-life (5.1 h). Interestingly, subchronic vortioxetine treatment failed to reverse scopolamine-induced social recognition memory deficits, and had no effects on basal hippocampal ACh levels. These data suggest that vortioxetine has some effects on memory that could be mediated through cholinergic neurotransmission. However, the effects are modest and are only seen under acute dosing conditions, which may argue against cholinergic mechanisms being the primary mediator of vortioxetine's cognitive effects, which are observed under chronic dosing conditions in patients with MDD.

JPET#233924

Introduction

Major Depressive Disorder (MDD) patients commonly experience impairments in cognitive function, including deficits in cognitive domains such as attention, executive function, speed of processing, and memory (McIntyre et al., 2013). These impairments are clinically important from the perspective that they may predict poor response to treatment with SSRIs (Dunkin et al., 2000; Withall et al., 2009), tend to remain prominent after recovery of mood symptoms (Herrera-Guzman et al., 2009; Herrera-Guzman et al., 2010); (Kuny and Stassen, 1995), and are associated with poor functional recovery (Jaeger et al., 2006). Thus, it is important to identify effective treatment strategies for MDD-associated cognitive dysfunction is important in order to achieve a functional recovery in MDD patients.

Vortioxetine is a multimodal antidepressant that is approved for the treatment of MDD. Evidence from clinical trials suggests that vortioxetine ameliorates some aspects of MDD-associated cognitive impairment, for example speed of processing, executive function and memory. This is supported by evidence from a number of preclinical experiments (du Jardin et al., 2014; Jensen et al., 2014; Wallace et al., 2014; Li et al., 2015). Much of the recent research efforts from our laboratory have been aimed at understanding the biological mechanism by which vortioxetine exerts these beneficial effects on cognitive function. Vortioxetine is a serotonin (5-HT) transporter protein (SERT) inhibitor, a 5-HT_{1A} receptor agonist, 5-HT_{1B} receptor partial agonist, and 5-HT_{1D}, 5-HT₃, and 5-HT₇ receptor antagonist (Sanchez et al., 2015). Interestingly, vortioxetine's 5-HT receptor activity may confer the ability to indirectly modulate signaling through several other neurotransmitter systems, including norepinephrine, dopamine (Pehrson et al., 2013), acetylcholine (ACh) and histamine (Mork et al., 2013), gamma-aminobutyric acid (GABA) (Pehrson and Sanchez, 2015; Dale et al., 2016), and glutamate (Dale et al., 2014;

JPET#233924

Pehrson and Sanchez, 2014; Riga et al., 2014). Several of these neurotransmitter systems have known relationships to cognitive function, and we have hypothesized that vortioxetine's cognitive effects may be specifically related to indirect modulation of GABA and glutamate neurotransmission (Pehrson and Sanchez, 2014), ACh or histamine neurotransmission (Mork et al., 2013). While these ideas are not necessarily mutually exclusive, it is important to empirically investigate the relationship between vortioxetine's effects on these neurotransmitter systems and cognition.

ACh neurotransmission has a well-documented relationship to cognitive function. Speaking generally, improvements of cognitive function can be consistently observed after cholinergic receptor activation while impairments tend to be observed after cholinergic receptor antagonism. For example, antagonism of muscarinic cholinergic receptors using scopolamine consistently impairs cognitive functions in domains such as attention, learning and memory in rodents and humans (Collerton, 1986; Molchan et al., 1992), and genetic models featuring deletions of muscarinic M₂ receptors show impairments in behavioral flexibility and working memory, as well as reductions in hippocampal long-term potentiation, an electrophysiological measure conceptually associated with memory function (Seeger et al., 2004). Antagonism of nicotinic $\alpha 7$ or $\alpha 4\beta 2$ cholinergic receptors also impairs memory function in rodents (Levin, 1992; Levin, 2002; Dobryakova et al., 2015). Moreover, improvements in cognitive performance or related electrophysiological measures have been observed after pharmacological activation of muscarinic or nicotinic receptor targets (Levin, 1992; Levin and Rezvani, 2002; Dennis et al., 2016). Acetylcholinesterase inhibitors such as donepezil, which increase synaptic availability of ACh by reducing the rate of catabolism, improve memory function not only in rodent models (e.g. (Zarrindast et al., 2002)), but also induce small but significant improvements in memory

JPET#233924

function in humans, whether in schizophrenic patients (see meta-analysis (Ribeiz et al., 2010), or in patients with Alzheimer's disease (see meta-analysis (Birks, 2006). Thus, it appears in general that activation of cholinergic neurotransmission, whether by direct pharmacological action on receptors or by increased ACh availability, may be a mechanism that can be leveraged to improve cognition across several different clinical populations.

These data may suggest that vortioxetine's indirect effects on cholinergic neurotransmission could represent a relevant mechanism for the observed improvements in cognitive function among MDD patients. Therefore, the purpose of the present paper is to empirically evaluate the relationship between vortioxetine's effects on ACh neurotransmission and cognition in preclinical animal models.

JPET#233924

Methods

Animals

A total of 321 adult male rats were used, i.e., 144 Wistar rats (Charles River Laboratories, France) for the social recognition memory tests, 69 Sprague Dawley OFA rats (Charles River Laboratories, France) for the object recognition experiments, 16 Sprague Dawley rats (Harlan Laboratories, Frederick, MD, USA) for the visual signal detection task (VSDT), and 92 Sprague Dawley rats (Charles River Laboratories, Indianapolis, IN, USA) for the *in vivo* microdialysis, *ex vivo* receptor occupancy, and pharmacokinetic interaction and exposure time course studies. Additionally, social recognition memory experiments used juvenile Wistar rats as stimulus animals that were not otherwise subjected to any experimental manipulations. All rats were group-housed in plastic cages under temperature- and humidity-controlled conditions, a 12 h light/dark cycle, and with *ad libitum* access to food and water, except where noted below. All procedures were performed in a manner consistent with local guidelines on ethical research in animals and were approved by the relevant authority or animal care and use committee prior to the start of experiments.

Drugs and chemicals

Vortioxetine HBr was synthesized by H. Lundbeck A/S. Scopolamine HBr trihydrate, and paroxetine maleate was purchased from Sigma-Aldrich. Donepezil HCl monohydrate was purchased from either Sigma-Aldrich or Sequoia Research Products, Ltd. SB216641 HCl was purchased from Tocris Biosciences. Vortioxetine was dissolved in a 20% (w/v) aqueous solution of 2-hydroxypropyl-beta-cyclodextrin (Roquette America, Inc., Keokuk, IA, USA) and injected subcutaneously (s.c.) at a volume of 2 mL/kg. Scopolamine and donepezil were dissolved in

JPET#233924

saline and injected s.c. at a volume of 1 mL/kg. Paroxetine and SB216641 were used in *ex vivo* autoradiography experiments and were dissolved in dimethylsulfoxide (Sigma-Aldrich). Specific information on the magnitude and timing of doses are reported below for each experiment type. All doses are expressed as the mass of the active base. Vortioxetine doses (10 mg/kg, s.c. acute and 1.8g per kg/food subchronically) were chosen to target the top of the clinically-relevant vortioxetine dose range based on *ex vivo* rat SERT occupancy experiments (Leiser et al., 2014). Doses of scopolamine and donepezil were chosen independently for each behavioral task based on the results of pilot experiments. In general, the doses used were the minimum required to induce a reliable effect in each behavioral task.

[³H]escitalopram (70 Ci/mmol; 1 mCi/mL) was synthesized at Amersham (Piscataway, NJ, USA), while the 5-HT_{1B} receptor antagonist [³H]GR125743 (76 Ci/mmol; 0.1 mCi/mL) was purchased from Perkin-Elmer (Boston, MA, USA).

Behavioral Experiments

Social Recognition Memory Task

The social recognition test was conducted as described by Lemaire et al. (Lemaire et al., 1994) with minor modifications. The test consists of 3 steps, an information trial (IT), a delay, and a retention trial (RT). During the IT, an unfamiliar juvenile rat was introduced into the home cage of an adult rat for 5 min, then removed for the duration of the delay, and reintroduced to the adult rat for the RT. During the IT and RT, the time the adult rat spent by the adult rat investigating the juvenile was recorded. Investigations were defined as sniffing, grooming, or closely following the juvenile rat.

JPET#233924

Control experiments were conducted to determine whether the pharmacological manipulations alter investigation behavior *per se*. For that purpose, adult rats were injected with vehicle or vortioxetine (10 mg/kg, 1 h s.c.) and scopolamine (0.25 mg/kg, 30 min s.c.) before an initial contact with an unfamiliar juvenile rat. The time spent investigating the juvenile rat was recorded. The rats used in these preliminary experiments were evenly distributed throughout the experimental groups and used in the main social recognition memory experiments after a 5-day washout.

In the study of acute vortioxetine, adult rats were randomly injected with vehicle or vortioxetine (0.1, 1, 3, or 10 mg/kg, 1 h s.c.) and vehicle or scopolamine (0.25 mg/kg, 30 min s.c.) prior to the IT. The delay lasted 30 min.

In the study of subchronic vortioxetine, adult rats were fed *ad libitum* for 14-15 days with either a vehicle food (Purina 5001) or food infused with 1.8 g of vortioxetine per kg food. On the test day, rats received vehicle or scopolamine (0.25 mg/kg, s.c.) and testing was performed as described above.

Object recognition memory task

The object recognition task was performed in a Plexiglas Y-maze apparatus (45 × 15 × 33 cm) placed in a room illuminated only by a halogen lamp orientated towards the ceiling, which produced a uniform dim light in the maze of approximately 60 Lux (Bartolini et al., 1996; Bertaina-Anglade et al., 2011). The objects were different in shape, color and texture. In addition, the objects were made of glass (white) and metal (grey), about 14 cm high and were too heavy to be moved by the rats. Each pair of objects was validated in previous experiments to ensure the absence of spontaneous preference for one of the pair. In each experiment, the role

JPET#233924

(familiar *versus* novel object) as well as the relative position of the two objects were counterbalanced and randomly permuted. Rats were placed in the experimental room for at least 30 min prior to testing.

The experiment consisted of 4 sessions. On days 1 and 2, rats received habituation sessions to the area and test room environment, in which animals were allowed to freely explore the apparatus for 10 min per day. On the third day, rats were submitted to two exploration trials with a 1 h inter-trial interval. During the information trial (IT; day 3, trial 1), animals were placed in the Y-maze containing 2 identical objects and were given 5 min to explore the objects before being returned to the home cage for the inter-trial interval. Exploration was defined as the animal having its head close to the object while looking at, sniffing, or touching the object. Any rat not exploring the objects for at least 15 s during the IT was excluded from the experiments. In the retention trial (RT; day 3, trial 2), animals were exposed to an identical copy of one of the objects previously seen during the first trial and a novel object. The RT lasted 5 min. The floor and walls of the y-maze, as well as the objects were washed with 10% ethanol and dried thoroughly after each trial. On day 3 rats were injected with vehicle, vortioxetine (3.9 or 7.9 mg/kg, s.c.) or donepezil (0.4 or 1.3 mg/kg, s.c) 1 h and with vehicle or scopolamine (3.47 mg/kg, s.c.) 55 min before the start of the IT.

Visual signal detection task (VSDT)

The VSDT was conducted in 4 identical operant chambers enclosed within sound attenuating cubicles (Med-Associates). Each chamber was equipped with a signal light mounted above a food cup (centered on the front panel), a house light, two retractable levers (on either side of the

JPET#233924

food cup), and a fan to provide ventilation and white noise. The visual signal consisted of an increased illumination intensity lasting for 500 ms.

The rats were trained and tested according to procedures adapted from previously published experiments, e.g. (Hillhouse and Prus, 2013; Freitas et al., 2015; Hillhouse et al., 2015). Briefly, each trial started with the house light and signal light on (background illumination of 0.9 lux). During training, a trial started with a consistent pre-signal interval of 4 s, which is the “attention” portion of the trial. After the pre-signal interval, rats experienced either a “blank” or “signal” trial for 500 ms. Under blank trial conditions, there was no change in the signal light illumination, while under signal trial conditions there was a 1.5 lux increase in illumination intensity of the signal light to 2.4 lux for 500 ms. Next, a post-signal interval of 1 s preceded the left and right levers extending into the chamber. If a rat pressed the signal-lever (randomly assigned as either the right or left lever) during a signal trial it was recorded as a “hit” and the rat received a food pellet. If a rat pressed the blank-lever during a blank trial it was recorded as a correct rejection and the rat received a food pellet. Levers were retracted after a response or 5 s (whichever occurred first). If rats failed to make a response in 5 s, then it was counted as an omission. Incorrect responses (i.e., blank-lever during a signal trial or signal-lever during a blank trial) and trial omissions resulted in no food pellet delivery and a 2 s time-out (all lights in test chamber turned off). Rats were trained until a criterion of $\geq 70\%$ choice accuracy was obtained for 3 consecutive sessions.

Test sessions were identical to training sessions except that 3 signal intensities were used (i.e., 0.4, 0.6 and 1.5 lux increase above blank conditions, order randomized) and pre-signal interval delays of 3, 6, and 12 s (order randomized) were used. Test sessions consisted of 90 blank trials and 90 signal trials (i.e., 30 low, 30 moderate, and 30 high signal intensity trials). Once the

JPET#233924

training criterion was met, test sessions occurred every third day. Animals received at least one training session immediately preceding a test session. Test sessions were conducted no more than twice a week (typically Tuesdays and Fridays) and were separated by at least 72 h. On test days, animals were injected with vehicle or vortioxetine (10 mg/kg, s.c.) 1 h followed by scopolamine (0.1 or 0.25 mg/kg, s.c.) 30 min prior to test session start. The order of drug combinations was determined by a randomized Latin-square design. The initial scopolamine 0.25 mg/kg dose was chosen because pilot experiments had demonstrated reliable impairment in VSDT performance at this dose. The 0.1 mg/kg dose was included in order to assess the extent to which vortioxetine's effects on scopolamine-induced VSDT performance depended on scopolamine dose.

Drug exposure studies

To assess a possible pharmacokinetic interaction between vortioxetine and scopolamine, a separate set of rats were treated with vehicle or vortioxetine (10 mg/kg, s.c.) 1 h and scopolamine (0.1 mg/kg, s.c.) or vehicle 30 min before sampling of plasma and brains. In addition, a separate set of experiments was made to determine the relationship between pretreatment time and plasma and brain concentration of vortioxetine 10 mg/kg, s.c. Towards this end, blood and brains were collected at 1, 2, 4, 8, 12, and 16 h after dosing. Rats were anesthetized using CO₂ and decapitated using a sharpened guillotine. Blood was collected into vacutainers containing EDTA and gently mixed for 30 s before placing on ice. Later, blood was centrifuged at 3000 rpm for 15 min at 4°C. The plasma layer was collected and frozen at -20°C until use. Brains were quickly dissected, flash frozen on powdered dry ice and stored at 20°C until analysis.

JPET#233924

Frozen brains were weighed and homogenized in 3x (weight/volume) of brain homogenization buffer (50% water, 30% 2-propanol and 20% dimethylsulfoxide). A 150 μ L internal standard (Lundbeck compound AA34745) solution was added to 50 μ L homogenized brain sample, which was then vortexed and centrifuged. The supernatant was collected for analysis of vortioxetine or scopolamine exposure. For plasma samples, the internal standard solution was added to the sample as described above before thorough mixing. In addition, standard curves for vortioxetine and scopolamine (0-4000 ng/ml in brain or 0-1000 ng/mL for plasma) were generated. The samples were injected directly into an Aria TLX2 coupled with a TSQ Quantum Ultra (both systems Thermo Electron, CA USA). A Gemini column (Kinetex 2.6 μ m C18, 50 x 2.1 mm, Phenomenex, Torrance, CA, USA) was used for analytical separation. A typical 3 min gradient with the following mobile phases was used: 0.1% formic acid in water (solvent A) and 0.01% formic acid in acetonitrile (solvent B). The mass spectrometer was equipped with a HESI probe and the source conditions were: vaporizer temp 450°C, spray voltage 3000, sheath gas at 40°C, ion sweep gas and aux gas at 20°C and capillary temperature at 300°C. Spectra were acquired in positive SRM mode with the parent masses of: vortioxetine 299.16 (m/z) and daughter ion (#1) 109 (m/z) at 37 collision energy (CE), daughter ion (#2) 150 (m/z) at 27 CE both at tube lens of 120; scopolamine 304.36 (m/z) and daughter ion (#1) 138 (m/z) at 20 CE and daughter ion (#2) 103 (m/z) at 25 CE, both at tube lens of 115; internal standard 552.32 (m/z) and daughter ion 203 (m/z) at 50 CE at tube lens of 120.

In vivo microdialysis experiments

Anesthetized (isoflurane, 2%, 800 mL/min O₂) rats were placed in a stereotaxic frame (Kopf instruments, USA) and implanted with CMA12 guide cannulas (CMA Microdialysis, Sweden) in the ventral hippocampus (coordinates: anteroposterior axis = -5.3mm relative to bregma,

JPET#233924

mediolateral axis = -4.8 mm relative to midline; dorsoventral axis = -8.0 mm relative to dura (Paxinos G, 1998). Skull screws were implanted and a head cap was constructed using dental cement. Lidocaine was used for local anesthesia and carprophen (5 mg/kg s.c.) was used as a pre- and post-operative analgesic. After surgery, animals were singly housed and allowed to recover for at least 7 days prior to the microdialysis experiments.

At 5 pm the day prior to the microdialysis experiments, a CMA12 microdialysis probe (PAES, 4 mm membrane length, 100 kDa pore size) was inserted into the guide cannula, the rat was placed in a plastic shoebox cage with bedding and connected to a 2 channel swivel (Instech Solomon, USA) and allowed to move freely. The probes were perfused at a constant flow rate of 1 μ L/min with a sterile artificial CSF solution (aCSF; CNS Perfusion Fluid, CMA Microdialysis, Harvard Apparatus, USA). The aCSF consisted of (in mM): 148 NaCl; 4 KCl; 0.8 MgCl₂, 1.4 CaCl₂, 1.2 Na₂HPO₄ (pH = 7.2). At 8 am the following morning, samples were collected into a refrigerated fraction collector (Honeycomb fraction collector, Bioanalytical Systems, Inc, USA) in 30 min intervals for 3 h to define the baseline. The first two samples were discarded from analysis. For the acute study, all animals were treated with saline upon collection of the final baseline sample, and subsequently with either vehicle or vortioxetine (10 mg/kg, s.c.) 1h after completion of baseline sample collection. Samples were then collected for 4 h. Experiments assessing the effects of subchronic vortioxetine on extracellular ACh were conducted as described above, with a few modifications. After surgery, rats were singly housed for 14 days, during which they were given 30 g/day of Purina 5001 rodent diet (vehicle), or the same amount of food infused with 1.8 g of vortioxetine per kg food. On day 15 probes were inserted and rats were perfused with aCSF at 1.5 μ L/min. After a 4 h stabilization period, samples were collected in 20 min intervals for 4 h in order to determine basal ACh levels. Given that the goal in this experiment was only to

JPET#233924

compare basal ACh levels in vehicle and subchronic vortioxetine treated groups, the small differences in perfusion rate and fraction collection time between the subchronic and acute dosing experiments are not theoretically important. After the completion of experiments, rats were anesthetized by CO₂ and decapitated. Brains were quickly dissected from the skull, flash frozen on powdered dry ice and stored at -20°C until used in *ex vivo* receptor occupancy experiments.

ACh standards were prepared in aCSF and were diluted prior to analysis by combining 10 µL of standard solution with 10 µL of a 1.0 ng/mL D-ACh solution prepared in distilled water. The range of standards was 10-100000 pg/mL. Microdialysis samples were prepared in the same manner (10 µL of sample and 10 µL of D-ACh stock solution) to provide 20 µL of sample for analysis. Samples and standards were prepared in plastic tubes (Bioanalytical Systems, Inc) which were loaded into a 96 deep well plate and then heat sealed (Thermo Scientific Easy Peel) prior to placing them onto the Acquity sample organizer for analysis.

A Waters Acquity HPLC system equipped with a Sunshell RP-Aqua 2.1x100 mm, 2.6 µm particle column was used to isolate ACh prior to detection using a Waters Quattro Premier XE triple quadrupole mass spectrometer operating in the MS/MS mode. A full loop injection using a 5 µL loop with a 4x overfill, requiring a total sample volume of 20 µL, was utilized to deliver samples onto the LC/MS/MS system. Column and tubing prior to column were maintained at 30°C. The mobile phase consisted of an aqueous component (A: 100 mM ammonium acetate in milliQ water) and an organic component (B: 100% acetonitrile). Isocratic elution of ACh (retention time 1.77 min) using 100% A followed by a wash of the column using a fast ramp to 100% B and then a re-equilibration of the column back to 100% A permitted separation of the two analytes with a total run time of 5 min. Detection of the analytes was performed by

JPET#233924

monitoring unique fragments formed from parent ions of ACh (parent [146.05 Da] to fragment [86.3 Da]). To correct for sample and instrument variability, a deuterated ACh (D-ACh) was incorporated into the samples to act as an internal standard (parent (149.95 Da) to fragment (90.15 Da)). Utilizing this technique, a lower limit of detection of 5 pg/mL was achieved.

2.6. *Ex vivo* target occupancy experiments

Ex vivo occupancy at the SERT and the 5-HT_{1B} receptor were determined after acute (10 mg/kg, s.c., 1 h) and subchronic (1.8 g/kg food for 15 days) vortioxetine. Rats were anesthetized with CO₂ and decapitated, and brains were dissected, frozen, and stored as described in section 2.5. *Ex vivo* occupancy experiments were performed as described in (du Jardin et al., 2014; Wallace et al., 2014). Briefly, frozen brain tissue was sectioned coronally at 20 μm thickness using a cryostat (MicroM, Germany) beginning at ~1.5-1.2 mm anterior to Bregma (Paxinos G, 1998). Slices were thaw mounted on glass microscope slides and stored at -20°C after being thoroughly dried. On the day of autoradiography experiments, plastic boxes containing slides were defrosted at room temperature for at least 30 min under a constant air flow. Following a brief pre-incubation at 4°C (5-HT_{1B} receptor occupancy only), slides were incubated for 1h in an assay buffer containing 50mM Tris HCl, 150 mM NaCl, and 5mM KCl, (pH=7.4) and 4.5 nM [³H]escitalopram (SERT occupancy) or 170 mM Tris HCl, 4mM CaCl₂, and 0.1% (w/v) L-ascorbic acid and 1 nM [³H]GR125743 (5-HT_{1B} receptor occupancy). Non-specific binding was determined on a separate slide by including with the radioligand a high concentration of a non-radioactive competitor selective for the target in question, i.e., 1μM paroxetine or 1μM SB216641 for SERT and 5-HT_{1B} receptor occupancy, respectively. After incubation, slides were washed twice in cold assay buffer and briefly dipped in cold distilled water. Slides were air dried under a fan for 30 min before being transferred to a vacuum desiccator for at least 1 h. Finally,

JPET#233924

an image of the slides was taken using a Beta-imager (Biospace lab, France) for 16 h.

2.7. Statistics

All data are presented as mean \pm SEM. The criterion for statistical significance was set at $\alpha = 0.05$ unless noted otherwise. Statistical analyses were conducted using either GraphPad Prism 6.0 for windows (GraphPad Software, La Jolla, CA, USA), or MATLAB (Mathworks, Natick, MA, USA).

Social recognition memory task: For assessment of drug effects on social exploration, the dependent measure was the time (s) spent investigating a juvenile stimulus animal during an initial exposure and data were analyzed using an independent samples t-test. Within the memory experiments, the dependent measure was a recognition index, defined as $IT/(IT+RT)*100$, where IT is defined as the investigation time during the information trial, and RT is the investigation time during the retention trial. Outliers were identified using Pierce's criterion (Ross, 2003) and removed. The data were subsequently analyzed by a one-way analysis of variance (ANOVA), followed where appropriate by Fisher's protected *t post-hoc* tests.

Object recognition task: Data were collected as time (s) spent actively exploring the familiar (F) or novel (N) object during RT. Recognition memory data are presented as a recognition index, defined as: $[(N - F) / (N + F)] \times 100$. Animals with low level of object exploration (novel + familiar <5 s) were excluded from the data analysis. Outliers were identified using Pierce's criterion (Ross, 2003) and removed. The data were subsequently analyzed by a one-way analysis of variance (ANOVA), followed where appropriate by Fisher's protected *t post-hoc* tests.

Visual Signal Detection Task: The dependent variables were: 1) Percent hits = (number of correct responses on signal trials/the number of signal trials completed) \times 100. 2) Percent correct

JPET#233924

rejections = (number of correct responses on blank trials/the number of blank trials completed) x 100. 3) Response latency = total time elapsed from when the levers were extended to when a lever press occurred / the number of trials completed (these data were collapsed across signal and blank trials). 4) Response omissions = total number of trials where no response occurred (these data were collapsed across signal and blank trials). A two-factor repeated measures ANOVA was applied with signal intensity and treatment condition as factors for percent hits. The F-values reported in text for this dependent measure relate to the treatment x stimulus intensity interaction effects. A one-way repeated measures ANOVA was used to assess the effect of treatment condition on percent correct rejections, response latency, or trial omissions. A significant ANOVA model was followed by a Fisher's protected *t post-hoc* test.

Drug exposure experiments: Scopolamine or vortioxetine plasma concentrations are expressed as nM and μ M, respectively, while brain concentrations are expressed as either nmol/kg or μ mol/kg. The brain to plasma ratio was calculated by dividing the brain concentration by plasma concentration. Data were analyzed using independent samples t-tests. In vortioxetine time course experiments, the peak vortioxetine level was determined empirically, and the elimination of vortioxetine from the plasma and blood was modeled using a one-phase exponential decay regression model.

Statistical analysis of microdialysis experiments was performed as reported previously (Pehrson et al., 2013). For the acute dosing study, the raw ACh concentrations were normalized to the average basal ACh concentrations observed in the vehicle group. Subsequently, the area under the curve (AUC) for each individual animal's normalized extracellular ACh concentration was calculated using the trapezoid method for fractions 4 through 9 (0-150 min on Figure 4), which constituted the entirety of vortioxetine's apparent time course on extracellular ACh

JPET#233924

concentrations. AUC data from the vehicle and vortioxetine groups were compared using unpaired two-tailed independent samples t-tests. This analytical method was preferred for its simplicity; however, similar significance values were observed using a more traditional two-factor ANOVA of normalized extracellular ACh concentrations, including data from all dialysate fractions. For the subchronic dosing study, the basal extracellular ACh concentration was defined for each animal by taking the average of all dialysate fractions collected. These basal values were normalized to the average basal concentration for the vehicle animals and compared using a two-tailed independent samples t-test.

JPET#233924

Results

Social recognition memory test

Vortioxetine treatment did not alter the basic drive for social interaction observed for scopolamine. Adult rats that were administered vehicle followed by 0.25 mg/kg scopolamine exhibited an investigation time of 55 ± 7 s, while rats administered 10 mg/kg vortioxetine followed by 0.25 mg/kg scopolamine investigated the juvenile stimulus animal for 51 ± 7 s ($t(18)=0.46$, n.s.).

In acute administration experiments, the vehicle + scopolamine-treated group had significantly reduced recognition index scores compared to vehicle controls ($F(5,96)=3.63$, $p<0.01$; Figure 1A), suggesting an impairment in social recognition memory. *Post-hoc* tests revealed that recognition index scores for animals pre-treated with vortioxetine 0.1-3 mg/kg before scopolamine administration were not significantly different from vehicle + scopolamine treated subjects. However, rats administered 10 mg/kg vortioxetine + scopolamine had significantly higher recognition index scores as compared to vehicle + scopolamine treated rats ($p<0.001$).

In subchronic administration experiments, animals fed vehicle food for 2 weeks followed by 0.25 mg/kg scopolamine 30 min s.c. on the day of experiments had significantly reduced recognition index scores *versus* animals fed vehicle food *ad libitum* followed by vehicle injection ($F(2,32)=3.7$, $p<0.05$; Figure 1B). *Post-hoc* tests demonstrated that recognition index scores in animals fed 1.8 g/kg vortioxetine food *ad libitum* followed by 0.25 mg/kg scopolamine 30 min s.c. were not significantly different from those observed in vehicle + scopolamine animals.

Object recognition memory

JPET#233924

Acute administration of scopolamine significantly reduced object recognition scores *versus* vehicle control subjects ($F(5,63)=23.02$, $p<0.001$; Figure 2). Recognition index scores in animals treated with 3.9 mg/kg vortioxetine were not significantly different from those in animals in the vehicle + scopolamine group. However, recognition index scores for animals in the 7.9 mg/kg vortioxetine + scopolamine group were significantly higher than those of animals in the vehicle + scopolamine group. Additionally, animals in the 0.4 mg/kg donepezil + scopolamine and 1.3 mg/kg donepezil + scopolamine groups had significantly higher recognition index scores as compared to the vehicle + scopolamine group.

Visual signal detection task

Scopolamine 0.25 mg/kg produced a significant reduction in percent hits ($F(6,84)=32.08$, $p<0.001$; Figure 3A) and correct rejections ($F(3,42)=29.49$, $p<0.001$; Figure 3B) *versus* the vehicle + vehicle condition. Vortioxetine 10 mg/kg did not influence scopolamine-induced deficits on percent hits or correct rejections. Vortioxetine by itself did not produce any significant changes in percent hits or correct rejections (Figure 3A, B). Similar effects were observed in other VSDT-dependent measures. Scopolamine 0.25 mg/kg significantly increased response latencies ($F(3,42)=120.20$, $p<0.001$; Supplemental table 1) and response omissions ($F(3,42)=59.27$, $p<0.001$; Supplemental table 1) *versus* vehicle controls, and vortioxetine significantly enhanced these effects. When administered alone, vortioxetine did not affect response latency or omissions.

Scopolamine 0.1 mg/kg also produced a significant reduction in percent hits ($F(6,90)=30.75$, $p<0.001$; Figure 3C) and correct rejection ($F(3,45)=22.92$, $p<0.001$; Figure 3D) *versus* vehicle controls. Pretreatment with 10 mg/kg vortioxetine did not alter these scopolamine-induced

JPET#233924

deficits. Consistent with the previous experiment, vortioxetine alone did not have any effect (Figure 3C, D). As observed with the higher scopolamine dose, 0.1 mg/kg scopolamine significantly increased the response latencies ($F(3,45)=128.30$, $p<0.001$; Supplemental table 1) and omissions ($F(3,45)=58.13$, $p<0.001$; Supplemental table 1) *versus* the vehicle + vehicle control group and vortioxetine enhanced these effects. Once again, vortioxetine by itself did not produce a significant effect.

Finally, the effects of the acetylcholinesterase inhibitor donepezil on the deficits induced by 0.1 mg/kg scopolamine were studied. As observed previously, 0.1 mg/kg scopolamine significantly impaired signal detection performance by decreasing the accuracy of percent correct hits ($F(6,84)=8.77$, $p<0.001$; Figure 3E) and rejections ($F(3,42)=13.97$, $p<0.001$; Figure 3F) *versus* the vehicle control group. Pretreatment with 3 mg/kg donepezil significantly improved scopolamine-induced deficits on percent correct hits (selectively at 2.4 lux stimulus intensity) and rejection accuracy (Figure 3E, F). Donepezil had no significant effects on percent correct hits or rejections when administered alone. As observed in previous trials, scopolamine increased response latencies ($F(3,42)=16.94$, $p<0.001$; Supplemental table 1) and omissions ($F(3,42)=3.3$, $p<0.05$; Supplemental table 1) *versus* vehicle controls. Donepezil had no effect by itself on these measures, but donepezil pretreatment reversed scopolamine-induced increases in response omissions (although scopolamine effects on omissions were small).

Drug exposure studies

Scopolamine exposure levels after scopolamine 0.1 mg/kg were unaffected by pretreatment with 10 mg/kg vortioxetine (plasma ($t(14)=1.56$, n.s.), brain ($t(14)=0.23$, n.s.), Table 1). The brain to plasma ratio of scopolamine was also unchanged ($t(14)=0.85$, n.s.). Rats treated with vortioxetine

JPET#233924

showed significantly higher vortioxetine plasma concentrations than animals treated with vortioxetine + scopolamine 0.1 mg/kg ($t(14)=2.74$, $p<0.05$). However, this did not translate into a difference in vortioxetine brain concentrations between the two treatment groups ($t(14)=0.13$, n.s.), or in the brain to plasma ratio ($t(14)=1.19$, n.s.).

Simple visual inspection of the time course for plasma and brain levels after 10 mg/kg vortioxetine shows peak plasma ($2.1 \pm 0.13 \mu\text{M}$) and brain ($660 \pm 19 \mu\text{mol/kg}$) exposure approximately 2 h after dosing (Figure 4). Further analysis of these data using non-linear regression revealed an apparent plasma half-life of 3.9h (95% confidence interval: 2.8-6.5 h) and the half-life in brain was calculated to be 5.1 h (95% CI: 3.4-10 h).

In vivo microdialysis measurement of extracellular ACh in the ventral hippocampus

In the acute dosing experiment, the mean basal extracellular ACh concentrations were 66 ± 15 and 69 ± 11 pg/mL, respectively, for the vehicle- and vortioxetine-treated groups (Figure 5). Acute vortioxetine injections produced a relatively small but statistically significant increase in extracellular ACh concentration *versus* the vehicle group ($t(12)=2.486$, $p<0.05$). The increase was short-lived and peaked at approximately 150% of basal concentrations from 60-90 min post-vortioxetine dose before quickly returning to basal levels by 3 h post-dose.

In the subchronic dosing experiment, extracellular ACh concentrations measured over a period of 3 h were 47 ± 7 and 50 ± 14 pg/mL, respectively, in vehicle- and vortioxetine (1.8 g/kg food)-treated animals (basal concentrations normalized to the average vehicle baseline was $100 \pm 16\%$ and $106 \pm 30\%$, respectively, Figure 6). These values did not differ statistically significantly ($t(12)=0.17$, n.s.).

JPET#233924

Ex vivo autoradiography experiments

Acute vortioxetine (10 mg/kg, s.c., 1h) produced ~99% SERT and 80 % 5-HT_{1B} receptor occupancy (Table 2). Similarly, animals treated subchronically with vortioxetine-infused food had 99% of SERT and 81% of 5-HT_{1B} receptors occupied.

JPET#233924

Discussion

This is the first in-depth study to empirically evaluate the proposed relationship between vortioxetine's effects on cognitive function and ACh neurotransmission. We found that acute vortioxetine reversed scopolamine-induced deficits in social and object recognition memory-related tasks, but not in an attention-related visual signal detection task. However, vortioxetine had no effect on social recognition memory after subchronic administration at an equivalent dose (Table 2). In line with previous observations in the prefrontal cortex (Mork et al., 2013), acute vortioxetine caused a small and transient but significant increase of hippocampal ACh. The transient nature of this effect on hippocampal ACh levels cannot be explained by vortioxetine's kinetics, since brain exposure did not peak until 2 h post-administration and the brain elimination half-life is 5.1 h. Furthermore, subchronic vortioxetine administration at an equivalent dose failed to alter basal hippocampal ACh levels. Overall, these data suggest that vortioxetine's effects on cholinergic neurotransmission are relatively small and short-lived, reducing the likelihood that altered cholinergic neurotransmission is the primary mechanism mediating vortioxetine's sustained positive effects on cognitive function.

In line with published evidence, we observed that dysregulating cholinergic neurotransmission via administration of the nonselective muscarinic receptor antagonist scopolamine induced significant deficits in social and object recognition memory performance in rats (Winslow and Camacho, 1995; Millan et al., 2007; Riedel et al., 2009; de Bruin et al., 2010); (Lieben et al., 2005; de Bruin and Pouzet, 2006; de Bruin et al., 2010). Acute vortioxetine administration significantly reversed scopolamine-induced memory deficits in these tasks, but only at the high end of the clinically relevant dose range (Leiser et al., 2014), i.e. a modest but significant effect at 10 mg/kg in the social recognition memory task and at 7.9 mg/kg in the object recognition

JPET#233924

task. Given the well-characterized relationship between dose and target engagement for this drug, these data may provide some hints at the receptor mechanisms that are relevant for vortioxetine's ability to reverse scopolamine-induced deficits. Vortioxetine selectively and fully occupies 5-HT₃ receptors at low doses (ED₈₀ = 0.1 mg/kg), and as the dose increases vortioxetine engages SERT (ED₈₀ = 1.2 mg/kg), 5-HT_{1B} receptors (ED₈₀ = 9 mg/kg), and 5-HT_{1A} and 5-HT₇ receptors (du Jardin et al., 2014; Leiser et al., 2014). Therefore, 5-HT₃ receptor antagonism and SERT inhibition appear to be insufficient alone, and either 5-HT_{1B} receptor partial agonism, 5-HT_{1A} receptor agonism, 5-HT₇ receptor antagonism, or some combination thereof is necessary for vortioxetine's effects in these tasks. However, since 5-HT receptor-mediated modulation of scopolamine-induced recognition memory deficits is poorly studied it is difficult to further evaluate our findings. Although acute vortioxetine reversed scopolamine-induced social recognition memory deficits, a similar effect was not observed in animals treated subchronically with an equivalent vortioxetine dose. The cause of this loss of efficacy is not yet understood, but may involve desensitization of the relevant receptor effect.

To examine whether elevation of extracellular ACh is mechanistically relevant for reversing scopolamine-induced object recognition memory deficits, we investigated the effects of acute treatment with the cholinesterase inhibitor donepezil. We found that acute donepezil (0.4 and 1.3 mg/kg) significantly attenuated scopolamine's effects. This agrees with published data showing that the cholinesterase inhibitors galantamine and metrifonate reversed scopolamine's effects in this model (Lieben et al., 2005; de Bruin and Pouzet, 2006; Lieben et al., 2005). We did not test donepezil in the social recognition memory task, but the literature has consistently shown that cholinesterase inhibition reverses scopolamine-induced deficits in this model (Winslow and Camacho, 1995; Millan et al., 2007; Riedel et al., 2009; de Bruin et al., 2010). Thus, it appears

JPET#233924

that elevating extracellular ACh concentrations can consistently reverse scopolamine's negative effects on recognition memory, although the precise receptor mechanism is unclear.

In line with previous reports, we observed that acute scopolamine administration significantly impairs VSDT performance (McQuail and Burk, 2006; Rezvani et al., 2009; Freitas et al., 2015). Acute vortioxetine failed to improve scopolamine-induced impairments of VSDT performance measures related to attention (i.e., hits and correct rejections) and accentuated scopolamine-induced deficits in response latency and omissions, measures that may be consistent with changes in arousal or motivation. This is likely a pharmacodynamic effect since co-administration of scopolamine and vortioxetine had no impact on brain concentrations of either drug. However, the mechanisms driving these effects on response latency and omissions are unknown. Vortioxetine alone consistently failed to alter performance in any of the VSDT-dependent measures, whereas donepezil (3 mg/kg) attenuated scopolamine-induced deficits. However, the effect was only partial and only observed at the highest signal intensity level. The 3 mg/kg donepezil dose is notably higher than the dose needed to reverse scopolamine-induced deficits in the object recognition test (0.4 mg/kg). Furthermore, a s.c. administration of this donepezil dose is expected to produce a marked increase in extracellular ACh. Thus, it appears that increasing extracellular ACh levels is insufficient to fully reverse scopolamine-induced VSDT deficits.

Vortioxetine at 10 mg/kg s.c. caused a relatively small, transient, but statistically significant increase in extracellular ACh in the ventral hippocampus. This observation is similar to our previously reported small and transient extracellular ACh increase in the prefrontal cortex (Mork et al., 2013). Thus, these data serve to further substantiate the presence of an indirect effect of vortioxetine on extracellular ACh, and to extend this effect to a new region of the brain. The

JPET#233924

precise receptor mechanism or downstream system-level mechanism that drives vortioxetine's effects on extracellular ACh cannot be empirically discerned based on these data and is outside the intended scope of the experiments presented here. However, given the vortioxetine dose-effect curve observed for cortical extracellular ACh (Mork et al., 2013), the responsible receptor mechanism must be one that becomes occupied to a biologically-meaningful level between 2.5 and 10 mg/kg vortioxetine, and is either present in cholinergic terminal regions such as the frontal cortex and hippocampus, or in the basal forebrain, where cholinergic fibers originate (McKinney M., 1983). Based on these restrictions, the receptor that is most likely to be involved is the 5-HT_{1B} receptor, which is on the ascending portion of its dose-occupancy curve between 2.5 and 5 mg/kg (Leiser et al., 2014), is present at high levels in both the medial frontal cortex and hippocampus (Dale et al., 2015; Pehrson et al., 2015) and has a demonstrated role in regulating ACh release (Consolo et al., 1996). It is also possible that the mechanism responsible requires a combination of vortioxetine's target pharmacological mechanisms, e.g. SERT inhibition and 5-HT_{1B} receptor partial agonism, or 5-HT₃ receptor antagonism and 5-HT_{1B} receptor partial agonism. Alternatively, it is possible that vortioxetine-induced increases of extracellular monoamine concentrations (Pehrson et al. 2013) are driving this effect indirectly at receptors for which vortioxetine has no pharmacological affinity. More empirical studies are required to investigate this mechanism further.

The presence of an acute vortioxetine-induced increase in extracellular ACh, in combination with our demonstration that the acetylcholinesterase inhibitor donepezil reverses some scopolamine-induced cognitive deficits, opens for the possibility that a portion of vortioxetine's effects in these models are due to an indirect increase in cholinergic receptor activation, for example at nicotinic receptors. Data from other labs suggests that activation of $\alpha 7$ (Roncarati R

JPET#233924

et al. 2009) or $\alpha 4\beta 2$ (Lange-Asschenfeldt C, Schable S et al. 2016 *Neuropharmacology* 107:100-10) nicotinic receptors is capable of attenuating scopolamine-induced deficits in object recognition memory in rodents. However, whether or not vortioxetine's effects on scopolamine-induced deficits are mediated via nicotinic receptor mechanisms or some other downstream mechanism cannot be evaluated based on the data presented here, and again these concepts are outside the intended scope of the present study.

Indeed, it is noteworthy that vortioxetine's effect on extracellular ACh is consistently transient. (Mork et al., 2013) showed significant increases in cortical extracellular ACh concentrations at 20 and 60 min post-dose only. In the present study, we observed significantly increased in hippocampal ACh concentrations at 60 and 90 min post-dose. However, as observed in the exposure time course data, vortioxetine reaches its peak exposure at 2 h post-dose and has a brain half-life of 5.1 h. Therefore, vortioxetine's short-lasting effect on ACh cannot be explained by a rapid elimination of drug, but is more likely ascribed to a fast desensitization of vortioxetine-induced activation at the relevant receptors, or the activation of a low-affinity vortioxetine receptor mechanism (for example agonism at the 5-HT_{1A} receptor or antagonism at the 5-HT₇ receptor), which limits the effects of the receptor mechanism responsible for vortioxetine-induced increases in ACh. The data presented here cannot differentiate between these possibilities. In line with the transient nature of the ACh response it is also important to note that subchronic vortioxetine resulted in no changes in basal extracellular ACh concentrations in the hippocampus. This is consistent with vortioxetine's inability to reverse scopolamine-induced impairments in social recognition memory task after subchronic administration.

JPET#233924

There are important caveats to consider when evaluating these data. Importantly, vortioxetine's affinity for rat 5-HT_{1A} and 5-HT₇ receptors is approximately an order of magnitude lower than for the human counterparts (Sanchez et al., 2015). Therefore, if vortioxetine's cholinergic mechanisms are mediated via effects at either of these targets, then our study may have underestimated the impact of the cholinergic system in clinical populations. Additionally, the behavioral data are limited to assessments of social recognition memory, object recognition memory, and attention; thus, caution should be exercised when extrapolating to other cognitive domains that are improved by vortioxetine in the clinic, e.g. processing speed and executive function (du Jardin et al., 2014; Jensen et al., 2014; Wallace et al., 2014; Li et al., 2015). Moreover, while the neurochemical data presented here may suggest that vortioxetine has limited effects on cholinergic neurotransmission, this should be viewed with caution until empirical evaluations of other cognitive domains have been evaluated. Furthermore, whether vortioxetine can modulate cognitive impairments induced by nicotinic, rather than muscarinic, receptor antagonism has not been evaluated in this study. Finally, given that these studies were conducted only in male rats these data may not necessarily translate in to females. Therefore, further studies are needed to evaluate vortioxetine's effects on nicotine receptor antagonist-mediated cognitive deficits, and to address whether there are sex differences in vortioxetine's effects on ACh neurotransmission.

In conclusion, our data suggest that vortioxetine has some effects on memory that could be mediated through cholinergic neurotransmission. However, the effects are only seen under acute dosing conditions, which may argue against cholinergic mechanisms being the primary mediator of vortioxetine's cognitive effects observed under chronic dosing conditions in patients with MDD.

JPET#233924

Acknowledgements

The authors wish to thank Theepica Jeyarajah and Christina Merritt for excellent technical assistance.

Author Contributions

Participated in Research Design: Pehrson, Hillhouse, Haddjeri, Rovera, Porter, Smagin, Budac, Cajina, Sanchez

Conducted Experiments: Pehrson, Hillhouse, Rovera, Song, Budac, Cajina

Performed Data Analysis: Pehrson, Hillhouse, Haddjeri, Rovera, Budac, Smagin, Song, Cajina

Wrote or Contributed to the Writing of the Manuscript: Pehrson, Hillhouse, Haddjeri, Rovera, Budac, Porter, Mørk, Smagin, Song, Cajina, Sanchez

JPET#233924

References

- Bartolini L, Casamenti F and Pepeu G (1996) Aniracetam restores object recognition impaired by age, scopolamine, and nucleus basalis lesions. *Pharmacology, biochemistry, and behavior* **53**:277-283.
- Bertaina-Anglade V, Drieu-La-Rochelle C, Mocaer E and Seguin L (2011) Memory facilitating effects of agomelatine in the novel object recognition memory paradigm in the rat. *Pharmacology, biochemistry, and behavior* **98**:511-517.
- Birks J (2006) Cholinesterase inhibitors for Alzheimer's disease. *Cochrane Database Syst Rev*:CD005593.
- Collerton D (1986) Cholinergic function and intellectual decline in Alzheimer's disease. *Neuroscience* **19**:1-28.
- Consolo S, Arnaboldi S, Ramponi S, Nannini L, Ladinsky H and Baldi G (1996) Endogenous serotonin facilitates in vivo acetylcholine release in rat frontal cortex through 5-HT 1B receptors. *The Journal of pharmacology and experimental therapeutics* **277**:823-830.
- Dale E, Pehrson AL, Jeyarajah T, Li Y, Leiser SC, Smagin G, Olsen CK and Sanchez C (2015) Effects of serotonin in the hippocampus: how SSRIs and multimodal antidepressants might regulate pyramidal cell function. *CNS Spectrums*.
- Dale E, Pehrson AL, Jeyarajah T, Li Y, Leiser SC, Smagin G, Olsen CK and Sanchez C (2016) Effects of serotonin in the hippocampus: how SSRIs and multimodal antidepressants might regulate pyramidal cell function. *CNS spectrums* **21**:143-161.
- Dale E, Zhang H, Leiser SC, Xiao Y, Lu D, Yang CR, Plath N and Sanchez C (2014) Vortioxetine disinhibits pyramidal cell function and enhances synaptic plasticity in the rat hippocampus. *J Psychopharmacol* **28**:891-902.
- de Bruin N and Pouzet B (2006) Beneficial effects of galantamine on performance in the object recognition task in Swiss mice: deficits induced by scopolamine and by prolonging the retention interval. *Pharmacol Biochem Behav* **85**:253-260.
- de Bruin NM, Prickaerts J, Lange JH, Akkerman S, Andriambelosen E, de Haan M, Wijnen J, van Drimmelen M, Hissink E, Heijink L and Kruse CG (2010) SLV330, a cannabinoid CB1 receptor antagonist, ameliorates deficits in the T-maze, object recognition and Social Recognition Tasks in rodents. *Neurobiol Learn Mem* **93**:522-531.
- Dennis SH, Pasqui F, Colvin EM, Sanger H, Mogg AJ, Felder CC, Broad LM, Fitzjohn SM, Isaac JT and Mellor JR (2016) Activation of Muscarinic M1 Acetylcholine Receptors Induces Long-Term Potentiation in the Hippocampus. *Cereb Cortex* **26**:414-426.
- Dobryakova YV, Gurskaya OY and Markevich VA (2015) Administration of nicotinic receptor antagonists during the period of memory consolidation affects passive avoidance learning and modulates synaptic efficiency in the CA1 region in vivo. *Neuroscience* **284**:865-871.
- du Jardin KG, Jensen JB, Sanchez C and Pehrson AL (2014) Vortioxetine dose-dependently reverses 5-HT depletion-induced deficits in spatial working and object recognition memory: A potential role for 5-HT1A receptor agonism and 5-HT3 receptor antagonism. *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology* **24**:160-171.
- Dunkin JJ, Leuchter AF, Cook IA, Kasl-Godley JE, Abrams M and Rosenberg-Thompson S (2000) Executive dysfunction predicts nonresponse to fluoxetine in major depression. *J Affect Disord* **60**:13-23.
- Freitas KC, Hillhouse TM, Leitl MD and Negus SS (2015) Effects of acute and sustained pain manipulations on performance in a visual-signal detection task of attention in rats. *Drug Dev Res* **76**:194-203.
- Herrera-Guzman I, Gudayol-Ferre E, Herrera-Guzman D, Guardia-Olmos J, Hinojosa-Calvo E and Herrera-Abarca JE (2009) Effects of selective serotonin reuptake and dual serotonergic-noradrenergic

JPET#233924

- reuptake treatments on memory and mental processing speed in patients with major depressive disorder. *J Psychiatr Res* **43**:855-863.
- Herrera-Guzman I, Herrera-Abarca JE, Gudayol-Ferre E, Herrera-Guzman D, Gomez-Carbajal L, Pena-Olvira M, Villuendas-Gonzalez E and Joan GO (2010) Effects of selective serotonin reuptake and dual serotonergic-noradrenergic reuptake treatments on attention and executive functions in patients with major depressive disorder. *Psychiatry Res* **177**:323-329.
- Hillhouse TM, Merritt CR and Porter JH (2015) Effects of the noncompetitive N-methyl-D-aspartate receptor antagonist ketamine on visual signal detection performance in rats. *Behav Pharmacol* **26**:495-499.
- Hillhouse TM and Prus AJ (2013) Effects of the neurotensin NTS(1) receptor agonist PD149163 on visual signal detection in rats. *Eur J Pharmacol* **721**:201-207.
- Jaeger J, Berns S, Uzelac S and Davis-Conway S (2006) Neurocognitive deficits and disability in major depressive disorder. *Psychiatry Res* **145**:39-48.
- Jensen JB, du Jardin KG, Song D, Budac D, Smagin G, Sanchez C and Pehrson AL (2014) Vortioxetine, but not escitalopram or duloxetine, reverses memory impairment induced by central 5-HT depletion in rats: evidence for direct 5-HT receptor modulation. *European neuropsychopharmacology: the journal of the European College of Neuropsychopharmacology* **24**:148-159.
- Kuny S and Stassen HH (1995) Cognitive performance in patients recovering from depression. *Psychopathology* **28**:190-207.
- Lange-Asschenfeldt C, Schable S, Suvorava T, Fahimi EG, Bisha M, Stermann T, Henning U, Kojda G (2016) Effects of varenicline on alpha4-containing nicotinic acetylcholine receptor expression and cognitive performance in mice. *Neuropharmacology* **107**: 100-110.
- Leiser SC, Pehrson AL, Robichaud PJ and Sanchez C (2014) Multimodal antidepressant vortioxetine increases frontal cortical oscillations unlike escitalopram and duloxetine--a quantitative EEG study in rats. *British journal of pharmacology* **171**:4255-4272.
- Lemaire M, Bohme GA, Piot O, Roques BP and Blanchard JC (1994) CCK-A and CCK-B selective receptor agonists and antagonists modulate olfactory recognition in male rats. *Psychopharmacology (Berl)* **115**:435-440.
- Levin ED (1992) Nicotinic systems and cognitive function. *Psychopharmacology (Berl)* **108**:417-431.
- Levin ED (2002) Nicotinic receptor subtypes and cognitive function. *J Neurobiol* **53**:633-640.
- Levin ED and Rezvani AH (2002) Nicotinic treatment for cognitive dysfunction. *Curr Drug Targets CNS Neurol Disord* **1**:423-431.
- Li Y, Abdourahman A, Tamm JA, Pehrson AL, Sanchez C and Gulinello M (2015) Reversal of age-associated cognitive deficits is accompanied by increased plasticity-related gene expression after chronic antidepressant administration in middle-aged mice. *Pharmacol Biochem Behav* **135**:70-82.
- Lieben CK, Blokland A, Sik A, Sung E, van Nieuwenhuizen P and Schreiber R (2005) The selective 5-HT6 receptor antagonist Ro4368554 restores memory performance in cholinergic and serotonergic models of memory deficiency in the rat. *Neuropsychopharmacology* **30**:2169-2179.
- McIntyre RS, Cha DS, Soczynska JK, Woldeyohannes HO, Gallagher LA, Kudlow P, Alsuwaidan M and Baskaran A (2013) Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. *Depression and anxiety* **30**:515-527.
- McKinney M. CJT, Hedreen J.C. (1983) Topographic analysis of the innervation of the rat neocortex and hippocampus by the basal forebrain cholinergic system. *J Comp Neurol* **217**:103-121.
- McQuail JA and Burk JA (2006) Evaluation of muscarinic and nicotinic receptor antagonists on attention and working memory. *Pharmacol Biochem Behav* **85**:796-803.
- Millan MJ, Di Cara B, Dekeyne A, Panayi F, De Groote L, Sicard D, Cistarelli L, Billiras R and Gobert A (2007) Selective blockade of dopamine D(3) versus D(2) receptors enhances frontocortical

JPET#233924

- cholinergic transmission and social memory in rats: a parallel neurochemical and behavioural analysis. *J Neurochem* **100**:1047-1061.
- Molchan SE, Martinez RA, Hill JL, Weingartner HJ, Thompson K, Vitiello B and Sunderland T (1992) Increased cognitive sensitivity to scopolamine with age and a perspective on the scopolamine model. *Brain Res Brain Res Rev* **17**:215-226.
- Mork A, Montezinho LP, Miller S, Trippodi-Murphy C, Plath N, Li Y, Gulinello M and Sanchez C (2013) Vortioxetine (Lu AA21004), a novel multimodal antidepressant, enhances memory in rats. *Pharmacology, biochemistry, and behavior* **105**:41-50.
- Paxinos G WC (1998) *The rat brain in stereotaxi coordinates*. Academic Press, San Diego.
- Pehrson AL, Cremers T, Betry C, van der Hart MG, Jorgensen L, Madsen M, Haddjeri N, Ebert B and Sanchez C (2013) Lu AA21004, a novel multimodal antidepressant, produces regionally selective increases of multiple neurotransmitters--a rat microdialysis and electrophysiology study. *European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology* **23**:133-145.
- Pehrson AL, Jeyarajah T and Sanchez C (2015) Regional distribution of serotonergic receptors: a systems neuroscience perspective on the downstream effects of the multimodal-acting antidepressant vortioxetine on excitatory and inhibitory neurotransmission. *CNS Spectr*:1-22.
- Pehrson AL and Sanchez C (2014) Serotonergic modulation of glutamate neurotransmission as a strategy for treating depression and cognitive dysfunction. *CNS spectrums* **19**:121-133.
- Pehrson AL and Sanchez C (2015) Altered gamma-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants. *Drug Des Devel Ther* **9**:603-624.
- Rezvani AH, Kholdebarin E, Cauley MC, Dawson E and Levin ED (2009) Attenuation of pharmacologically-induced attentional impairment by methylphenidate in rats. *Pharmacol Biochem Behav* **92**:141-146.
- Ribeiz SR, Bassitt DP, Arrais JA, Avila R, Steffens DC and Bottino CM (2010) Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature. *CNS Drugs* **24**:303-317.
- Riedel G, Kang SH, Choi DY and Platt B (2009) Scopolamine-induced deficits in social memory in mice: reversal by donepezil. *Behav Brain Res* **204**:217-225.
- Riga M, Celada P, Sanchez C and Artigas F (2014) Cortical and hippocampal microcircuits involved in the mechanism of action of the new antidepressant drug vortioxetine. *Neuropsychopharmacology* **39**:S632.
- Roncarati R, Scali C, Comery T A, Grauer SM, Aschmi S, Bothmann H, Jow B, Kowal D, Gianfriddo M, Kelley C, Zanelli U, Ghiron C, Haydar S, Dunlop J, Terstappen GC (2009) Procognitive and neuroprotective activity of a novel alpha7 nicotinic acetylcholine receptor agonist for treatment of neurodegenerative and cognitive disorders. *Journal Pharmacology Experimental Therapeutics* **329**: 459-468.
- Sanchez C, Asin KE and Artigas F (2015) Vortioxetine, a novel antidepressant with multimodal activity: review of preclinical and clinical data. *Pharmacol Ther* **145**:43-57.
- Seeger T, Fedorova I, Zheng F, Miyakawa T, Koustova E, Gomeza J, Basile AS, Alzheimer C and Wess J (2004) M2 muscarinic acetylcholine receptor knock-out mice show deficits in behavioral flexibility, working memory, and hippocampal plasticity. *J Neurosci* **24**:10117-10127.
- Wallace A, Pehrson AL, Sanchez C and Morilak DA (2014) Vortioxetine restores reversal learning impaired by 5-HT depletion or chronic intermittent cold stress in rats. *Int J Neuropsychopharmacol* **17**:1695-1706.
- Winslow JT and Camacho F (1995) Cholinergic modulation of a decrement in social investigation following repeated contacts between mice. *Psychopharmacology (Berl)* **121**:164-172.

JPET#233924

- Withall A, Harris LM and Cumming SR (2009) The relationship between cognitive function and clinical and functional outcomes in major depressive disorder. *Psychol Med* **39**:393-402.
- Zarrindast MR, Bakhsha A, Rostami P and Shafaghi B (2002) Effects of intrahippocampal injection of GABAergic drugs on memory retention of passive avoidance learning in rats. *J Psychopharmacol* **16**:313-319.

JPET#233924

Footnotes

Conflict of interest statement.

Alan Pehrson, Arne Mork, Gennady Smagin, Dekun Song, David Budac, Manuel Cajina, and Connie Sanchez were employees of Lundbeck Research USA, Inc while these studies were conducted. Lundbeck employees played a role in study design, execution, and analysis, as well as in the writing of and decision to submit this manuscript. Nasser Haddjeri received funding from Lundbeck Research USA, Inc to conduct the object recognition experiments presented here. Joseph Porter received funding from Lundbeck Research USA, Inc to conduct the VSDT experiments presented here. Other authors have no conflicts to report.

JPET#233924

Figure Legends

Figure 1. Vortioxetine effects on scopolamine-induced social recognition memory

impairments. (A). Acute treatment with 0.25 mg/kg scopolamine significantly impaired social recognition memory performance. Acute vortioxetine treatment at 0.1-3 mg/kg did not significantly reverse scopolamine-induced impairments in this task, although 10 mg/kg vortioxetine did. **(B)** Acute scopolamine impaired social recognition memory performance, but subchronic treatment with vortioxetine (1.8 g vortioxetine/kg of food, *p.o. ad libitum*) failed to reverse scopolamine-induced deficits. N = 12-24 rats per group. Plus signs represent significant differences in *post-hoc* tests from the vehicle/vehicle condition (+, $p < 0.05$; ++, $p < 0.01$), while asterisks represent significant differences *versus* the vehicle/scopolamine treatment group (***, $p < 0.001$).

Figure 2. Vortioxetine effects on scopolamine-induced object recognition memory

impairments. Acute treatment with 3.47 mg/kg scopolamine significantly impaired object recognition memory performance. 3.9 mg/kg vortioxetine did not reverse scopolamine-induced impairments, but 7.9 mg/kg induced a significant improvement in performance compared to scopolamine alone. Donepezil (Don) treatment at either 0.4 or 1.3 mg/kg significantly improved object recognition performance compared to scopolamine alone. N = 9-18 rats per group. Plus signs represent significant differences from the vehicle/vehicle treatment group (****, $p < 0.0001$), while asterisks represent significant differences *versus* the vehicle/scopolamine group (*, $p < 0.05$; **, $p < 0.01$; ***, $p < 0.001$; ****, $p < 0.0001$).

Figure 3. Effects of vortioxetine and donepezil on scopolamine-induced impairments of visual signal detection task (VSDT) performance. Left panels show effects of a given

JPET#233924

treatment on scopolamine-induced deficits in percent correct hits. Right panels show effects of a given treatment on scopolamine-induced deficits in percent correct rejections. (A,B) Acute treatment with 0.25 mg/kg scopolamine (Scop) significantly impaired VSDT performance, and these impairments were not reversed by 10 mg/kg vortioxetine. (C,D) Acute treatment with 0.1 mg/kg scopolamine also significantly impaired VSDT performance, and again 10 mg/kg vortioxetine did not reverse these effects. (E,F) 0.1 mg/kg scopolamine once again significantly impaired VSDT performance. Acute treatment with 3 mg/kg donepezil (Don) induced a small but significant improvement compared to scopolamine alone, which was limited to the 2.4 lux stimulus intensity. N = 15-16 rats per group. Asterisks represent significant differences from vehicle/vehicle (+, $p < 0.05$; ++, $p < 0.01$; +++, $p < 0.001$). Plus signs represent significant differences from vehicle/scopolamine (*, $p < 0.05$; ***, $p < 0.001$).

Figure 4. Time course of vortioxetine exposure in plasma and brain after acute 10 mg/kg s.c. treatment. (A) Plasma vortioxetine exposure peaked at 2 h post-dose and had an apparent half-life of 3.9 h (95% confidence interval 2.8-6.5 h). (B) Brain vortioxetine exposure peaked at 2 h post dose and had an apparent half-life of 5.1 h (95% confidence interval 3.4-10 h). N = 3 per group.

Figure 5. Acute vortioxetine effects on extracellular acetylcholine concentrations in the ventral hippocampus. (A) Acute 10 mg/kg vortioxetine treatment induced a transient and relatively small but significant increase in hippocampal extracellular acetylcholine (ACh) compared to vehicle control animals. (B) Comparison of the area under the curve for vehicle- and vortioxetine-treated animals. N = 6-8 rats per group. Asterisks represent significant differences from the vehicle control group (*, $p < 0.05$; **, $p < 0.01$).

JPET#233924

Figure 6. Subchronic vortioxetine effects on basal extracellular acetylcholine

concentrations in the ventral hippocampus. 14-day treatment with vortioxetine-infused food

(1.8 g vortioxetine/kg food, p.o., *ad libitum*) failed to alter basal extracellular acetylcholine

(ACh) concentrations compared to vehicle controls. N = 5-7 rats per group. (n.s., not significant).

JPET#233924

Table 1. No pharmacokinetic interactions exist between acute vortioxetine and scopolamine. Bioanalysis of plasma and brain exposure to vortioxetine and scopolamine using administration routes and times relevant for the behavioral experiments presented in this study reveal no pharmacokinetic interactions between vortioxetine and scopolamine. Data are presented as mean \pm standard error. N = 8 rats per group. a. significant difference from vortioxetine + scopolamine group.

Treatment group	Vortioxetine			Scopolamine		
	Plasma (μ M)	Brain (μ mol/kg)	Brain:Plasma	Plasma (nM)	Brain (nmol/kg)	Brain:Plasma
Scopolamine (0.1 mg/kg, s.c., 30 min)	0	0	0	60 \pm 6.2	330 \pm 60	5.7 \pm 1.1
Vortioxetine (10 mg/kg, s.c., 1 h)	2.3 \pm 0.1 ^a	34 \pm 2.6	15 \pm 1.1	0	0	0
Vortioxetine (10 mg/kg, s.c. 1 h) + scopolamine (0.1 mg/kg, s.c.,30 min)	1.9 \pm 0.08	34 \pm 2.9	17 \pm 1.4	74 \pm 7.1	340 \pm 60	4.6 \pm 0.6

JPET#233924

Table 2. Estimated fractional target occupancy values at the SERT and 5-HT_{1B} receptor

after acute or subchronic vortioxetine administration. Vortioxetine occupied the same fraction of SERT and 5-HT_{1B} receptor targets using acute administration at 10 mg/kg 1 h s.c. or 14 day p.o. administration via *ad libitum* feeding with rodent chow infused with 1.8 g vortioxetine/kg of food weight. Thus, these dosing regimen are considered equivalent. Data are presented as Mean ± SEM. N = 6 rats per group.

Treatment Condition	Estimated Target Occupancy (%)	
	SERT	5-HT _{1B} receptor
Vortioxetine (10 mg/kg, s.c., 1 h)	99 ± 1.4	80 ± 2.9
Vortioxetine (1.8 g/kg food weight <i>ad libitum</i> 14 days)	99 ± 0.7	81 ± 2.6

Figure 1





Figure 2








Figure 3

Vortioxetine + 0.25 mg/kg Scopolamine



Vortioxetine + 0.1 mg/kg Scopolamine



Donepezil + 0.1 mg/kg Scopolamine





Figure 4





Figure 5





Figure 6

